Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.78
INCY's Cash to Debt is ranked higher than
54% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. INCY: 0.78 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.78

Equity to Asset -0.11
INCY's Equity to Asset is ranked higher than
52% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INCY: -0.11 )
INCY' s 10-Year Equity to Asset Range
Min: -1.83   Max: 0.84
Current: -0.11

-1.83
0.84
F-Score: 3
Z-Score: 6.57
M-Score: -0.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 0.97
INCY's Operating margin (%) is ranked higher than
84% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. INCY: 0.97 )
INCY' s 10-Year Operating margin (%) Range
Min: -6050   Max: 9.05
Current: 0.97

-6050
9.05
Net-margin (%) -11.23
INCY's Net-margin (%) is ranked higher than
80% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. INCY: -11.23 )
INCY' s 10-Year Net-margin (%) Range
Min: -5750   Max: 7.67
Current: -11.23

-5750
7.67
ROA (%) -8.72
INCY's ROA (%) is ranked higher than
82% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. INCY: -8.72 )
INCY' s 10-Year ROA (%) Range
Min: -70.43   Max: 5.19
Current: -8.72

-70.43
5.19
ROC (Joel Greenblatt) (%) 11.24
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. INCY: 11.24 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38   Max: 47.33
Current: 11.24

-4727.38
47.33
Revenue Growth (3Y)(%) 19.50
INCY's Revenue Growth (3Y)(%) is ranked higher than
90% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INCY: 19.50 )
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4   Max: 454
Current: 19.5

-61.4
454
EPS Growth (3Y)(%) 29.10
INCY's EPS Growth (3Y)(%) is ranked higher than
93% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INCY: 29.10 )
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1   Max: 64.9
Current: 29.1

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

INCY Guru Trades in Q4 2013

Paul Tudor Jones 5,423 sh (New)
Vanguard Health Care Fund 4,457,643 sh (+17.08%)
Steven Cohen 107,338 sh (+9.09%)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 202,580 sh (-3.45%)
Mariko Gordon 128,959 sh (-20.5%)
» More
Q1 2014

INCY Guru Trades in Q1 2014

George Soros 23,200 sh (New)
Vanguard Health Care Fund 4,901,968 sh (+9.97%)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc Sold Out
Mariko Gordon 112,623 sh (-12.67%)
Steven Cohen 42,149 sh (-60.73%)
» More
Q2 2014

INCY Guru Trades in Q2 2014

Ken Fisher 12,225 sh (New)
Louis Moore Bacon 100,000 sh (New)
Vanguard Health Care Fund 9,591,143 sh (+95.66%)
George Soros Sold Out
Mariko Gordon 23,728 sh (-78.93%)
» More
Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-09-30 Reduce -38.28%$45.35 - $55.78 $ 71.5743%7545
Vanguard Health Care Fund 2014-06-30 Add 95.66%0.68%$43.1 - $56.39 $ 71.5740%9591143
Mariko Gordon 2014-06-30 Reduce -78.93%0.19%$43.1 - $56.39 $ 71.5740%23728
George Soros 2014-06-30 Sold Out 0.01%$43.1 - $56.39 $ 71.5740%0
Ken Fisher 2014-06-30 New Buy$43.1 - $56.39 $ 71.5740%12225
George Soros 2014-03-31 New Buy0.01%$49.94 - $68.83 $ 71.5716%23200
Mariko Gordon 2013-12-31 Reduce -20.5%0.06%$34.71 - $51.34 $ 71.5765%128959
Vanguard Health Care Fund 2013-06-30 Add 21.52%0.05%$19.07 - $24.49 $ 71.57228%3807443
Vanguard Health Care Fund 2013-03-31 New Buy0.29%$16.61 - $24.95 $ 71.57250%3133100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp Ltd

Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Aramark, Incyte Corp Ltd. and Facebook Inc. Read more...
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Aramark, Incyte Corp Ltd, Emeritus Corp, and Huntsman Corp. Read more...
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Pandora Media Inc, Incyte Corp Ltd, Google Inc, and American Airlines Group Inc. Read more...

Ratios

vs
industry
vs
history
P/S 24.50
INCY's P/S is ranked higher than
74% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. INCY: 24.50 )
INCY' s 10-Year P/S Range
Min: 7.19   Max: 209.75
Current: 24.5

7.19
209.75
EV-to-EBIT 2616.87
INCY's EV-to-EBIT is ranked higher than
87% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 2616.87 )
INCY' s 10-Year EV-to-EBIT Range
Min: -672   Max: 3136.5
Current: 2616.87

-672
3136.5
Current Ratio 5.32
INCY's Current Ratio is ranked higher than
76% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. INCY: 5.32 )
INCY' s 10-Year Current Ratio Range
Min: 1.51   Max: 21.14
Current: 5.32

1.51
21.14
Quick Ratio 5.31
INCY's Quick Ratio is ranked higher than
77% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. INCY: 5.31 )
INCY' s 10-Year Quick Ratio Range
Min: 1.51   Max: 21.14
Current: 5.31

1.51
21.14

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.15
INCY's Price/Median PS Value is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. INCY: 1.15 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 15.77
Current: 1.15

0.1
15.77

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp Ltd was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company's drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries. The Company's trademaks include Incyte and JAKAFI. The Company's operations are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of the employees.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Our Partners
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day Dec 19 2014 - ZACKS

More From Other Websites
Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference Dec 23 2014
Incyte (INCY) Gains on Positive Baricitinib Study Results Dec 10 2014
Lilly, Incyte Arthritis Drug Meets Endpoint Dec 09 2014
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to... Dec 09 2014
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to... Dec 09 2014
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to... Dec 09 2014
For Treatment Of Polycythemia Vera, FDA Approves Jakafi, A Targeted Therapy Dec 05 2014
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera Dec 05 2014
FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia... Dec 04 2014
Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase... Dec 02 2014
Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase... Dec 02 2014
5 Critical Biotech Drug Dates and Events for December Dec 01 2014
5 Stock-Moving Medtech Events This December Nov 28 2014
Moving Average Crossover Alert: Incyte (INCY) Nov 21 2014
New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System Nov 20 2014
3 Drugs Stocks Driving The Industry Higher Nov 19 2014
Incyte Building Blockbuster Drug One Disease At A Time Nov 17 2014
Incyte to Present at Upcoming Investor Conferences Nov 17 2014
Incyte to Present at Upcoming Investor Conferences Nov 17 2014
INCYTE CORP Financials Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK